A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NSCLC Clinical Trial

Official title:

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04871997
• Other study ID #: S1040
• Status: Completed
• Start date: July 12, 2019
• Est. completion date: July 16, 2022

Study information

• Verified date: October 2022
• Source: Tongji Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.

Description:

A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.This study is a non-interventional, prospective, observational, real-world case study and all registered data are collected from real clinical practice cases. Adult patients diagnosed as advanced non-small cell lung cancer and treated with anlotinib were included. At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm.The primary endpoint was progression-free survival (PFS) and the secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.If the last patient reaches the main evaluation index or has intolerable toxic reaction, the observation will be finished, and the first one will prevail.Through Electronic Data Capture System (EDC) system, electronic case report form (eCRF) is used to replace paper-based case report form to collect and manage clinical trial data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 373
• Est. completion date: July 16, 2022
• Est. primary completion date: July 16, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age: =18 years old, no gender limit.

2. Diagnosed as advanced non-small cell lung cancer.

3. At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is =10 mm.

4. Doctors evaluate the benefits of receiving Anlotinib treatment.

5. The patient voluntarily joins the project and signs the informed consent. If any of the above items is "No", the patient is not suitable for this study.

Exclusion Criteria:

1. Those who have been confirmed to be allergic to anlotinib and/or its excipients.

2. Patients with anlotinib contraindications.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC

Locations

Country	Name	City	State
China	Hubei province	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Qian Chu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression-free survival (PFS)	the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse	2019.7-2022.7
Secondary	overall survival (OS)	the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.	2019.7-2022.7
Secondary	objective response rate (ORR)	the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment	2019.7-2022.7
Secondary	disease control rate (DCR)	the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.	2019.7-2022.7